News
A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...
Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- ...
For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.
The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.
Covid-19 and RSV head data scientist dramatically quits saying she doesn’t trust RFK Jr department to use it ‘objectively’ - ...
The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
The infection commonly referred to as RSV has started losing its hold in other parts of the country, and Dr. Theresa Cullen — the county’s health director — said Wednesday during a news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results